The evolution of treatment options for HIV-infected patients has both simplified and complicated the selection of an initial ARV regimen. PI-based regimens have always been associated with the absence of PI resistance mutations and with less NRTI resistance at the time of treatment failure. The rationale for using initial NNRTI-based regimens, on the other hand, has been their efficacy and simplicity. A number of recent head-to-head trials have illustrated the complexities involved in comparing the outcomes associated with these initial regimens and the effect of these regimens on future treatment options.

In this on-demand Web activity, an expert panel discusses and interprets the findings of these recent clinical trials. The Web activity strongly emphasizes the resistance outcomes of these trials and presents information about the range of available therapeutic options.